LEOSS

Lean European Open Survey on SARS CoV II Infected Patients

[Sandra Ciesek @CiesekSandra]

Wir suchen Verstärkung in der Forschung, PostDoc, gern mit virolog. Vorerfahrung, Bewerbungen bis 02.01.22, weitere Infos hier: https://t.co/1InKCvTyPa

[Sandra Ciesek @CiesekSandra]

unsere ersten Daten zur
Neutralisation von Omicron versus Delta sind fertig: 2x Biontech, 2x Moderna, 1xAZ/1x Biontech nach 6 Monaten 0% Neutralisation bei Omicron, auch 3x Biontech 3 Monate nach Booster nur 25% NT versus 95% bei Delta. Bis zu 37fache Reduktion Delta vs. Omicron

[Sandra Ciesek @CiesekSandra]

Auch wichtig- die Antigentests (3 verschiedene von Roche, Siemens und Flowflex) sind auch bei Omicron positiv und funktionieren!

[Olaf Gersemann @OlafGersemann]

Corona-Lage am 29.10.2020 (links):
⏺️ Wildtypus
⏺️ 0% Impfquote
⏺️ Inzidenz = 99
⏺️ 1696 Intensivpatienten
⏺️ 367 Tote in 7 Tagen

Corona-Lage am 29.10.2021 (rechts):
⏺️ Delta
⏺️ 69% Impfquote
⏺️ Inzidenz = 139
⏺️ 1868 Intensivpatienten
⏺️ 585 Tote in 7 Tagen

@welt

[ORCHESTRA-Cohort @orchestracohort]

As a European🌍 and international🗺️ network of multidisciplinary teams collaborating on scientific research 🧪🧬🧮of COVID-19, ORCHESTRA aims to work together for a broader understanding of the disease. Interested? Please check out our collaborations site: https://t.co/LyM9747r0U

[LEOSS @LEOSS_CoV_2]

@mfkuepp I usually agree that the recently hyped PK/PD discussion is in desperate need of meaningful evidence and not matching my clinical experience. But in this case, I'm with Axel: for Enterobacter spp., the resistance mec is well established and breakthroughs frequently reported.

[LEOSS @LEOSS_CoV_2]

Stanislas Werfel's group designed the CAPS-D score for #COVID19 with @LEOSS_CoV_2 data and is particularly exciting: simple to calculate, good #prediction, and relies only on cheap and universally available clinical parameters. Check out the preprint! https://t.co/od5mqFblIS

[LEOSS @LEOSS_CoV_2]

@SZ Deutsche Unikliniken nehmen an >200 Studien zu #COVID19 teil https://t.co/zFQ1BY3eSx, bieten fast allen Patient*innen eine Studienteilnahme an. Die 1seitige Darstellung ist eine Gemeinheit für die vielen Studienteams, die für uns alle ihre Freizeit opfern und Gesundheit riskieren

[LEOSS @LEOSS_CoV_2]

Open data comes at a cost - hundreds of hours of analysis for the perfect anonymization algorithms. The result: unbiased results in a deidentified dataset open for public use here https://t.co/yt7itdBGxd. Worth every minute. Thanks to @ArxDev for a great job & tireless effort!

[ARX @ArxDev]

Our new paper describes how we implemented data #anonymization pipelines with #ARX to enable the sharing of data on the epidemiology and clinical course of #SARS_CoV_2 infected patients. Great collabration with the team from @LEOSS_CoV_2! Link:
https://t.co/tD1mrAD0pj

[LEOSS @LEOSS_CoV_2]

LEOSS just included patient no. 5,000. We are humbled by the continued activity of our study centers in these difficult times. Remember, LEOSS is a community study that does not pay a dime. Our investigators sacrifice their spare time to improve our understanding of #COVIDー19.

[LEOSS @LEOSS_CoV_2]

First report of the LEOSS cancer cohort is online! Check it out here: https://t.co/Z3T48UAWOz #COVID19 #Cancer

[DZIF (inaktiv) @DZIF_]

We are very proud of what the DZIF has acchieved in 2019. Read more in our Annual Report: https://t.co/4mxXPZdd1b
#DZIF_annualreport #infectionreserach #translationalresearch

[LEOSS @LEOSS_CoV_2]

Well done @rki_de, every German plz grab a copy. Make @LEOSS_CoV_2 obsolete!

[phoenix @phoenix_de]

Vorstellung der #CoronaWarnApp, u.a. mit Horst Seehofer, @jensspahn, @HBraun & @DoroBaer https://t.co/9v7EtgOU3c

[LEOSS @LEOSS_CoV_2]

We are hiring, PostDoc + PhD in translational cancer outcomes, and you'd be part of the great team that brought you #LEOSS 😏 @DKTK_ @DKFZ

[LEOSS @LEOSS_CoV_2]

@CiesekSandra bit simple though. all diseases at fixed rates (rates from previous years?), only COVID-19 has an actual dynamic.

[NFDI - @[email protected] @NFDI_de]

Unser erster #FD_Tipp ist europäisch: https://t.co/I4RenqOMcw
@LEOSS_CoV_2
#lifesciences

[German Biobank Node @bbmri_de]

Our newsletter #COVID19 is out! https://t.co/cmfQQR3VT4 Topics: interview with Thomas Illig @MHHPublicHealth and Janne Vehreschild about @LEOSS_CoV_2 study, GBN webinar recordings, #DeCOI initiative and much more! Subscribe here: https://t.co/7bqz3keeRy #biobank #biobanking

[Sylvia Thun @ProfThun]

Morgen 14 Uhr im @hih2025 :

Premiere: Der ‚Bundeseinheitliche Forschungsdatensatz zu COVID-19‘

Konsens aller Universitätskliniken auf Basis internationaler Standards👏🏻

@LEOSS_CoV_2 @hl7germany @SnomedCT @LOINC @HiGHmed_MI @MIRACUM_de #SMITH #DIFUTURE @sitigde

#GECCO 🌍

[LEOSS @LEOSS_CoV_2]

Remember how we reported that Monday was our day with highest documentation activity yet? Well, that was almost doubled on Tuesday. Incredible. #COVID19

[LEOSS @LEOSS_CoV_2]

To all the #DataScientists: we are very sorry for the delay, #anonymization pipeline is behind schedule. We know you are waiting and this remains among our top priorities. Publishing data is a high risk for patient #privacy and we must do this 100% on the first try. #COVID19